Huadong Medicine reports solid growth, ramps innovation and global expansion

Huadong Medicine (SZSE:000963) has released its 2024 Annual Report, showcasing steady financial performance amidst industry challenges. Operating revenue reached CNY41.906 billion, a 3.16% increase year-over-year, while net profit attributable to shareholders surged 23.72% to CNY3.512 billion. The company's bolstered results come as it actively implements its "Improvement of Quality and Return" Action Plan. This strategy emphasizes innovation, enhanced operational efficiency, and sustainable development.